Nestlé rolls out its Sinergity nutrition product throughout Middle East

MIDDLE EAST – Nestlé, a giant food company, has rolled out its Sinergity, a science-based early-life-nutrition product, throughout Latin America and the Middle East, with launches in additional parts of Asia planned for later this year.

Under the NAN brand, Sinergity is a proprietary blend that combines probiotics with six human milk oligosaccharides (HMOs) structurally identical to those found in breastmilk.

According to the company, this combination helps contribute to a more favourable gut environment and stronger immunity in early childhood.

Laurent Alsteens, Global Head of Infant and Early Childhood Nutrition at Nestlé, stated that the company is leading the way in offering advanced, science-based nutritional solutions.

He noted that Nestlé’s products containing HMOs are available in more than 50 countries. Alsteens emphasized that, as parents look for the best options for their children, Nestlé continues to invest in products with proven benefits, fostering the growth of trusted brands in this sector.

Indonesia Approves dsm-firmenich’s 2’-FL HMO

This news comes as Indonesia officially grants safety clearance for DSM-Firmenich’s 2’-Fucosyllactose (2’-FL) human milk oligosaccharide (HMO) ingredient, marking a significant milestone for the company’s expansion in the region.

The approval, issued by the Indonesia Biosafety Clearing House, paves the way for the inclusion of Glycare 2FL 9000 in flavoured liquid milk drinks designed for children aged three and older.

Anita Wichmann, Lead Expert in Regulatory Affairs for Early Life Nutrition, Medical Nutrition, and HMOs at DSM-Firmenich, stated that emerging evidence continues to highlight the extensive health benefits of HMOs, from early life nutrition through to adulthood.

She noted that the newly secured market access for GLYCARE® 2FL 9000 presents fresh opportunities for innovators in Indonesia to incorporate these benefits into nutritional solutions aimed at supporting gut health in both children and adults.

The regulatory body determined that DSM-Firmenich’s 2’-FL ingredient is non-toxic, does not cause allergies, and is safe for consumption, reinforcing its role as a key component in early life nutrition. HMOs, naturally found in human breast milk, are widely recognized for their gut microbiota-supporting properties, aiding digestion, immunity, and overall health.

With this approval, DSM-Firmenich strengthens its presence in the global market, securing access to over 165 countries where its HMO products are now permitted.

“This safety clearance is a significant step forward in dsm-firmenich’s mission to improve access to HMOs worldwide, with ingredients from our GLYCARE^® HMO portfolio now available for use in more than 165 countries,” comments Elaine Tan, Regulatory Affairs Manager for the Asia-Pacific team at dsm-firmenich.

Subscribe to receive our email newsletters with the latest news and insights from Africa, Middle East and around the world. SUBSCRIBE HERE